Skip to content

Study · Not a test of the peptide alone · 1995

8 results

An improved imaging agent for malignant melanoma, based on [Nle4,D-Phe7]alpha-melanocyte stimulating hormone.

Bard DR

Nuclear medicine communications1 Oct 1995Cited by 4 (Europe PMC)

PMID8570117 (opens in a new tab)DOI10.1097/00006231-199510000-00010 (opens in a new tab)PepBankPUB-08570117
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Pharmacokinetics

    In DBA2 mice with Cloudman S91 melanomas, both NDP-MSH-DTPA compounds targeted indium-111 to the tumours.

    In plain wordsIn mice with melanoma, both NDP-MSH-based imaging compounds carried a radioactive label to the tumours.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableTargeting of indium-111 to melanomas
    Study

    mousen: not reported in source

    Cloudman S91 melanomas in DBA2 mice
    Outcome group
    Pharmacokinetics · Cancer

    Source sentences

    Summary
    Both compounds were able to target 111In to Cloudman S91 melanomas in DBA2 mice.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Pharmacokinetics

    In mice with melanoma, monoNDP-MSH-DTPA gave the highest tumour:blood and tumour:tissue ratios of the two compounds.

    In plain wordsIn mice with melanoma, the single-peptide imaging compound gave the highest tumour-to-blood and tumour-to-tissue ratios of the two compounds.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableTumour:blood and tumour:tissue ratios of monoNDP-MSH-DTPA
    Study

    mousen: not reported in source

    Cloudman S91 melanomas in DBA2 mice
    Outcome group
    Pharmacokinetics · Cancer

    Source sentences

    Summary
    MonoNDP-MSH-DTPA gave the highest tumour:blood and tumour:tissue ratios

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  3. 03AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Pharmacokinetics

    In mice with melanoma, monoNDP-MSH-DTPA showed the least unspecific radioactivity in the liver and kidney.

    In plain wordsIn mice with melanoma, the single-peptide imaging compound left the least unwanted radioactivity in liver and kidney.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableUnspecific liver and kidney radioactivity of monoNDP-MSH-DTPA
    Study

    mousen: not reported in source

    Cloudman S91 melanomas in DBA2 mice
    Outcome group
    Pharmacokinetics · Cancer

    Source sentences

    Summary
    MonoNDP-MSH-DTPA gave the highest tumour:blood and tumour:tissue ratios and showed least unspecific radioactivity in the liver and kidney.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  4. 04AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Pharmacokinetics

    In mice, radioscintigraphy showed good tumour localization of indium-111 with both compounds, and clear images within 2 h of injection.

    In plain wordsIn mice, both imaging compounds showed the tumour clearly on scans within 2 hours of injection.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableRadioscintigraphy tumour localization
    Study

    mousen: not reported in source

    Cloudman S91 melanomas in DBA2 mice
    Outcome group
    Pharmacokinetics · Cancer

    Measurements

    Time to clear images
    ≤ 2 h
    after injection

    Source sentences

    Summary
    Radioscintigraphy of mice showed good tumour localization of 111In with both compounds, clear images being obtainable within 2 h of injection.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  5. 05AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Pharmacokinetics

    In mice, scans with monoNDP-MSH-DTPA showed some kidney and thyroid radioactivity but no liver radioactivity.

    In plain wordsIn mice, scans with the single-peptide imaging compound showed some radioactivity in kidney and thyroid but none in the liver.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableOrgan radioactivity on scans with monoNDP-MSH-DTPA
    Study

    mousen: not reported in source

    Cloudman S91 melanomas in DBA2 mice
    Outcome group
    Pharmacokinetics · Cancer

    Source sentences

    Summary
    Scans with monoNDP-MSH-DTPA showed some kidney and thyroid but no liver radioactivity

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  6. 06AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Pharmacokinetics

    In mice, bisNDP-MSH-DTPA gave extensive abdominal radioactivity, most of it in the liver and kidneys.

    In plain wordsIn mice, the double-peptide imaging compound left much radioactivity in the abdomen, mostly in liver and kidneys.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableAbdominal radioactivity on scans with bisNDP-MSH-DTPA
    Study

    mousen: not reported in source

    Cloudman S91 melanomas in DBA2 mice
    Outcome group
    Pharmacokinetics · Cancer

    Source sentences

    Summary
    whereas bisNDP-MSH-DTPA gave extensive abdominal radioactivity, most of which was associated with the liver and kidneys.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  7. 07AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Pharmacokinetics

    In mice, monoNDP-MSH-DTPA was cleared from the tumour much less rapidly and gave more favourable tumour:blood ratios than other alpha-MSH derivatives investigated previously.

    In plain wordsIn mice, the single-peptide imaging compound stayed in the tumour longer and gave better tumour-to-blood ratios than earlier alpha-MSH compounds.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableTumour clearance and tumour:blood ratio of monoNDP-MSH-DTPA
    Study

    mousen: not reported in source

    Cloudman S91 melanomas in DBA2 mice
    Comparator
    other alpha-MSH derivatives previously investigated
    Outcome group
    Pharmacokinetics · Cancer

    Source sentences

    Summary
    MonoNDP-MSH-DTPA was cleared from the tumour much less rapidly and gave more favourable tumour:blood ratios than other alpha-MSH derivatives previously investigated.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  8. 08LabNot a test of Melanotan I (afamelanotide) aloneOther designActivity measurement

    NDP-MSH-DTPA conjugates with one or two peptides bound indium-111 stably and showed hormonal activity as great or greater than alpha-MSH.

    In plain wordsIn lab tests, two NDP-MSH-based imaging compounds held a radioactive label stably and were at least as active as alpha-MSH.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableIndium-111 binding and hormonal activity of NDP-MSH-DTPA conjugates
    Study

    n: not reported in source

    Comparator
    alpha-MSH
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    These two compounds (monoNDP-MSH-DTPA and bisNDP-MSH-DTPA, respectively) bound indium-111 (111In) stably and showed hormonal activity as great or greater than alpha-melanocyte stimulating hormone (alpha-MSH).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.